WO2012030057A2 - 자기활성화 림프구 배양용 배지 조성물 및 이를 이용한 자기활성화 림프구 배양방법 - Google Patents
자기활성화 림프구 배양용 배지 조성물 및 이를 이용한 자기활성화 림프구 배양방법 Download PDFInfo
- Publication number
- WO2012030057A2 WO2012030057A2 PCT/KR2011/004013 KR2011004013W WO2012030057A2 WO 2012030057 A2 WO2012030057 A2 WO 2012030057A2 KR 2011004013 W KR2011004013 W KR 2011004013W WO 2012030057 A2 WO2012030057 A2 WO 2012030057A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- culture
- self
- cells
- culturing
- medium
- Prior art date
Links
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 133
- 238000012258 culturing Methods 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title claims abstract description 38
- 239000013028 medium composition Substances 0.000 title claims abstract description 30
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 63
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 63
- 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 54
- 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 54
- 229940117681 interleukin-12 Drugs 0.000 claims abstract description 54
- 102000003810 Interleukin-18 Human genes 0.000 claims abstract description 43
- 108090000171 Interleukin-18 Proteins 0.000 claims abstract description 43
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 35
- 229930182816 L-glutamine Natural products 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 239000001963 growth medium Substances 0.000 claims description 29
- 238000012136 culture method Methods 0.000 claims description 27
- 239000006143 cell culture medium Substances 0.000 claims description 17
- 239000000654 additive Substances 0.000 claims description 13
- 239000002609 medium Substances 0.000 claims description 11
- 230000000996 additive effect Effects 0.000 claims description 9
- 210000005259 peripheral blood Anatomy 0.000 claims description 8
- 239000011886 peripheral blood Substances 0.000 claims description 8
- 238000012546 transfer Methods 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims 2
- 239000011259 mixed solution Substances 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 abstract description 71
- 210000004027 cell Anatomy 0.000 abstract description 48
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 34
- 201000011510 cancer Diseases 0.000 abstract description 27
- 210000000581 natural killer T-cell Anatomy 0.000 abstract description 17
- 230000001965 increasing effect Effects 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 238000011282 treatment Methods 0.000 abstract description 5
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 description 29
- 206010028980 Neoplasm Diseases 0.000 description 28
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000003213 activating effect Effects 0.000 description 10
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 9
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 8
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 8
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 8
- 108091008874 T cell receptors Proteins 0.000 description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 5
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 5
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 5
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 230000036210 malignancy Effects 0.000 description 4
- 210000005087 mononuclear cell Anatomy 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000004557 Interleukin-18 Receptors Human genes 0.000 description 2
- 108010017537 Interleukin-18 Receptors Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- NWNOWCGAHDFNFJ-RUCXOUQFSA-N (2s)-2,5-bis(azanyl)-5-oxidanylidene-pentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(N)=O.OC(=O)[C@@H](N)CCC(N)=O NWNOWCGAHDFNFJ-RUCXOUQFSA-N 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 230000035986 JAK-STAT signaling Effects 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 102100039063 Protein IL-40 Human genes 0.000 description 1
- 101710200420 Protein IL-40 Proteins 0.000 description 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 230000010632 Transcription Factor Activity Effects 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 102000004114 interleukin 20 Human genes 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008593 response to virus Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2318—Interleukin-18 (IL-18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
Definitions
- the present invention relates to a medium composition for culturing self-activated lymphocytes and a method of culturing self-activated lymphocytes using the same, and more particularly, to interleukin 2 (IL-2) and interleukin 12 (IL-12) in a medium.
- interleukin 2 IL-2
- IL-12 interleukin 12
- anti-CD3 and anti-CD16 antibodies are added together to efficiently amplify and activate Natural Killer (NK) cells, T cells, and NKT cells, and at the same time, the relative proportion of NK cells in lymphocyte cells.
- the present invention relates to a medium composition for culturing self-activated lymphocytes and a method for culturing self-activated lymphocytes using the same, which are capable of culturing immune cells having excellent efficacy in treating various types of malignancies by dramatically increasing the amount of cellulose.
- adoptive immunotherapy which can replace conventional surgery, radiation therapy, and chemotherapy, has attracted attention.
- Quantum immunotherapy involves the extraction of immune cells, which are most important for cancer treatment, from natural killer cells (NK cells), dendritic cells (DCs), B cells, and T cells.
- NK cells natural killer cells
- DCs dendritic cells
- B cells B cells
- T cells T cells
- NK cells are a kind of lymphocytes. They are excellent in killing infected viruses and tumor cells, and most normal cells do not kill.
- NK cells are known to play an important role in early biodefense mechanisms and tumor immunity of the human body.
- NK cells can kill specific magnetic cells, allogeneic cells, or even heterologous cancer cells without the immunization process according to the expression of the major histocompatibility complex (MHC), and in particular, express or less express Class1 MHC. Do not kill target cells better.
- MHC major histocompatibility complex
- NK cells can effectively kill most cancer cells that do not express MHC, as well as kill some virus-infected cells and bacteria such as salmonella typhi.
- NK cells which have an excellent effect on killing cancer cells, occupy only 5 to 15% of peripheral blood lymphocytes even in normal humans, and especially in cancer patients, the ratio decreases to less than 1%. There is a limit to effectively attack cancer cells without a separate amplification process through.
- CD4 T cell activation method Such conventional immune cell culture medium has been disclosed in Korean Patent No. 0735081 (name of the invention: CD4 T cell activation method).
- CD4 T cells are isolated from biological samples such as blood, and the isolated CD4 T cells are cytokine containing GM-CSF, IFN-gamma, TNF-alpha, Lectin, and IL-4.
- a composition for preventing or treating bacterial infectious diseases can be obtained.
- the medium composition used in the CD4 T cell activation method selectively activates only T cells involved in acquired immunity among immune cells, when applied to tumor treatment, T cells activated in large quantities for cancer cells memorized beforehand Effective attack and killing through cells is possible, but there is a problem in that there is a limit in treating malignant tumors by attacking various kinds of cancer cells which are not remembered.
- Korean Patent Publication No. 2008-0053929 name of the invention: self-activating lymphocyte culture method filed by the present applicant in order to solve this problem, lymphocytes isolated from human peripheral blood interleukin 2 (IL-2) And cultured in the presence of anti-CD3, anti-CD16 and anti-CD56 antibodies to increase the proportion of NK cells in lymphocyte cells, thereby activating the NK cells, T cells and NKT cells evenly to effectively remove various types of cancer cells. It is disclosed how to.
- IL-2 human peripheral blood interleukin 2
- FIG. 1 and 2 are graphs showing the phenotypic changes of activated lymphocytes obtained through the self-activating lymphocyte culture method, wherein the H1 region is NK cells, the H4 region is T cells, the H2 region is NKT cells, and the H3 region is a cell of other immune cells. The distribution is shown.
- the expansion of the NK cell weight and the increase in the titer thereof through the activation of immune cells can increase the killing ability against cancer cells, thereby improving the effective anticancer effect.
- the medium composition for culturing lymphocytes and the method of culturing activated lymphocytes using the same are constantly being studied.
- anti-CD3 and anti-CD16 antibodies are added together with interleukin 2 (IL-2), interleukin 12 (IL-12), and interleukin 18 (IL-18) in a medium.
- IL-2 interleukin 2
- IL-12 interleukin 12
- IL-18 interleukin 18
- Amplifying and activating NK cells, T cells, and NKT cells efficiently, and dramatically increasing the relative proportion of NK cells in lymphocyte cells, thereby cultivating immune cells that are effective in treating various types of malignancies. It is an object of the present invention to provide a medium composition for activating lymphocyte culture and a method for culturing self-activated lymphocyte using the same.
- a medium composition for culturing self-activated lymphocytes according to the present invention is composed of a cell culture medium and an additive added to the cell culture medium, and the medium composition for mass culturing self-activated lymphocytes, wherein the additive is Interleukin 2 (IL-2), interleukin 12 (IL-12), interleukin 18 (IL-18), and anti-CD3 and anti-CD16 antibodies.
- IL-2 Interleukin 2
- IL-12 interleukin 12
- IL-18 interleukin 18
- anti-CD3 and anti-CD16 antibodies anti-CD3 and anti-CD16 antibodies.
- Self-activating lymphocyte culture method comprises the steps of extracting lymphocytes from human peripheral blood;
- the extracted lymphocytes were interleukin 12 (IL-12), interleukin 18 (IL-18), and antileukin in culture medium to which interleukin 2 (IL-2), L-glutamine, and autologous plasma were added.
- the medium composition for self-activating lymphocyte culture and the method for culturing self-activated lymphocytes using the same according to the present invention efficiently amplify and activate NK cells, T cells, and NKT cells, and at the same time, the relative proportion of NK cells in the lymphocyte cells is better.
- the prognosis of cancer patients suffering from various types of malignant tumors by increasing the number of cancer cells that do not express MHC through mass activated NK cells can be applied to quantum immunotherapy with less side effects and less administration. The effect is to maximize the improvement.
- FIG. 1 is a graph showing a phenotypic change of activated lymphocytes obtained through a culture method according to the prior art.
- Figure 2 is a graph showing the phenotype change of activated lymphocytes obtained through the culture method according to the prior art.
- Figure 3 is a graph showing the phenotype change of activated lymphocytes obtained through the self-activating lymphocyte culture method according to the present invention.
- Figure 4 is a graph showing the phenotype change of activated lymphocytes obtained through the self-activating lymphocyte culture method according to the present invention.
- Figure 5 is a graph showing a comparison of the change in NK cell number obtained through the self-activated lymphocyte culture method according to the present invention and the change in NK cell number obtained through the self-activated lymphocyte culture method according to the prior art.
- Figure 6 is a graph showing the result of comparing the results of titer analysis for activated lymphocytes cultured through the self-activated lymphocyte culture method according to the present invention and the activated lymphocytes cultured through the conventional method for activating lymphocyte culture method.
- interleukin 12 IL-12
- interleukin 18 IL-
- Anti-CD3 and anti-CD16 antibodies are used as additives to efficiently amplify and activate NK cells, T cells, and NKT cells, while increasing the relative proportion of NK cells, thereby increasing self-activating lymphocytes excellent for treating malignancies. How to create.
- NK cells are a type of lymphocyte that is characterized by large granular lymphocytes (LGL), and its antitumor activity occurs in necrosis, apoptosis, or both mechanisms. It is done by NK cells respond to cytokines such as IL-2, IL-12, Interferon, and the like, thereby raising cytotoxicity, secretory, and proliferative functions.
- Phenotypes of NK cells are CD16 (Fc ⁇ RIII) and CD56 in humans. CD16 and CD56 do not have a T-cell receptor complex (TRC) on the cell surface and are used as markers for NK cells.
- TRC T-cell receptor complex
- IL-2 is a glycoprotein with a molecular weight of 14 to 17 kDa, which is produced when T cells recognize and activate an antigen, secreted out of T cells, and then reacted with the T cells that produced IL-2 itself. Promotes cell growth. IL-2 also acts on NK cells to promote growth, enhances NK cell killing capacity, and acts on B cells to promote their growth.
- IL-12 is produced by dendritic cells (DCs), macrophages and B cells.
- DCs dendritic cells
- IL-12 induces the production of IFN- ⁇ and TNF- ⁇ in NK cells and T lymphocytes, and reduces the production of IL-4 that inhibits IFN- ⁇ . It also increases the cytotoxicity of NK cells and CD8 + cytotoxic T lymphocytes.
- IL-12 is closely related to IL-2 signaling in NK cells.
- IL-2 induces expression of IL-12 receptor ⁇ 1 and IL-12 receptor ⁇ 2 in NK cells to express and activate proteins related to IL-12 signaling system. This mechanism is well demonstrated in the ability of NK cells to produce IFN- ⁇ and target cell killing.
- the IL-12 receptor ⁇ 2 appears to play an important role in IL-12 function, which has been reported to inhibit the development of Th2 and to advance the development of Th1.
- IL-12 signaling in T cells and NK cells is involved in the JAK-STAT signaling system, and the activity of IL-12 receptor ⁇ 2 plays an important role in inducing and activating phosphorylation of the transcription factor STAT4.
- IL-18 is produced from macrophages and is a proinflamatory cytokine gene. IL-18 binds to the IL-18 receptor and, together with IL-12, produces an immune response to bacteria or virus-infected cells and increases the production of IFN- ⁇ in NK and T cells.
- IL-12 is added to the culture medium to induce the expression of INF- ⁇ , and NK cells are activated by inducing the expression of the receptor IL-18 which is an essential factor for the production of INF- ⁇ .
- NK cells express CD16, a receptor for Fc of immunoglobulin G (IgG), through which other forms of MHC non-limiting killing can be performed.
- the ADCC of NK cells depends on the presence of an antibody that recognizes the target cell.
- the Fc region of the antibody is exposed, and when the exposed Fc region binds to the receptor of the NK cell to form a bridge, Signaling caused by receptor binding releases cytotoxic substances from NK cells, causing target cells to be injured.
- CD16 antigen When lymphocytes are cultured in the presence of an anti-CD16 antibody or an antigen-antibody complex, CD16 antigen is added to NK cells and signal transduction occurs. Expression or tumor necrosis factor (TNF) or IFN- ⁇ can be produced.
- TNF tumor necrosis factor
- a T cell refers to a cell having an T cell receptor (TCR) on its cell surface.
- TCR forms a heterodimer with the CD3 antigen of the di- and ⁇ -chain dimers. Some of the T cells (around 5% of peripheral blood T cells) are dimers of ⁇ and ⁇ chains, not ⁇ .
- TCR forms a complex with the CD3 antigen ( ⁇ , ⁇ , ⁇ , ⁇ , ⁇ or ⁇ ), which plays a role in delivering the signal into the cell when TCR recognizes the antigen.
- helper T cells that promote an immune response to cancer cells release various cytokines to activate killer T cells, B cells, macrophages, and NK cells.
- the types of cytokines transfer information between cells.
- There are various substances such as IL-1, IL-2, IL-3, TNF- ⁇ and IFN- ⁇ .
- a high concentration of IL-2 is added to the culture medium to activate immune cells such as T cells, NK cells, and NKT cells.
- NKT cells are a type of T cell whose function is being revealed relatively recently as an attendant of endogenous immunity. As the name suggests, it expresses T-cell receptors and NK cell-specific surface markers.
- One surprising feature of NKT cells is the rapid release of several cytokines such as IL-4, IL-10, IL-13, IFN- ⁇ , TNF- ⁇ after activation. This feature suggests that NKT cells can have a significant effect on the adaptive immune response.
- T cells and NKT cells from lymphocytes of human peripheral blood IL-2, IL-12 and IL-18 cytokines, and anti-CD3 and anti-CD16 monoantibodies in culture was used as a medium additive, IL-2, IL-12 and IL-18 in the addition of T cells and NK cells, and each single antibody plays the role of antigens that express CD3, CD16 in immune cells .
- Self-activating lymphocyte culture process is largely composed of lymphocyte extraction step, the first culture step, the second culture step and the third culture step.
- the first medium composition is used in the first culture step, and consists of a medium for cell culture and various additives added to the cell culture medium, based on 39 ml of cell culture medium, for immune cell culture. 17 ⁇ 10 6 to 19 ⁇ 10 6 for activation of immune cells, with 350 to 430 ⁇ l of L-glutamine and 2 to 5 mL of autologous plasma of 190-210 mM L-glutamine 3-10 ⁇ l of IU / ml IL-2, 3-10 ⁇ l of 90-12 g / ml IL-12 and 10-30 ⁇ l of 90-110 ⁇ g / ml IL-18, and finally cultured immune cells (NK Cells, NKT cells, T cells) by adding 2 ⁇ 30ul of 0.9 ⁇ 1.1mg / ml anti-CD3 and anti-CD16 antibody to control the relative composition ratio of each.
- 3 to 4 Medium cultured with lymphocytes daily may be incorporated into a second medium composition having the following composition to further culture for 1-2 days.
- the second medium composition is used for subculture, and 190-210 mM L-glutamine (L-) acts as a nutrient for immune cell culture based on the cell culture medium based on 67 ml of the cell culture medium.
- L- L-glutamine
- glutamine 650 to 740 ⁇ l and 2 to 5 ml of autologous plasma, 17 ⁇ 10 6 to 19 ⁇ 10 6 IU / ml IL-2 3.5 to 7.8 ⁇ l
- Cell culture medium used in the first and second medium composition is 800 to 1200 IU (International Unit) / in a conventional medium containing nutrients essential for the growth and survival of cells, such as amino acids, vitamins, organic-inorganic compounds, proteins, etc.
- a medium containing ml of IL-2 NKB6040 (NKBIO, KOREA) is mentioned as an example.
- the self-activating lymphocyte culture process consists of a lymphocyte extraction step, a first culture step, a second culture step and a third culture step.
- mononuclear cells such as human lymphocytes or monocytes, having a specific gravity lower than 1.077
- the blood of the patient to be treated is superimposed on 1.077 specific gravity Ficoll-Paque Plus solution and centrifugally precipitated at a constant centrifugal force.
- the red blood cells and granulocyte layers larger than 1.077 are separated, and the mononuclear cell layer and platelets, which are 1.077 or less, are separated upward to obtain a mononuclear cell layer containing lymphocytes, and only lymphocytes are extracted from the separated mononuclear cell layers.
- Lymphocytes harvested through the lymphocyte extraction step were prepared in the presence of IL-12, IL-18, anti-CD3 and anti-CD16 antibodies in culture medium to which IL-2, L-glutamine, and autologous plasma were added. Incubate for 3-4 days.
- lymphocytes are first cultured in the presence of anti-CD3 antibody in a culture medium to which IL-2, L-glutamine and autologous plasma are added, followed by the presence of IL-12 and anti-CD16 antibody and IL-18. It is preferable to sequentially culture in the environment, the specific process is as follows.
- the harvested lymphocytes were suspended in 5 ml of culture medium, and then 2-10 ⁇ l of diluent containing 17 ⁇ 10 6 to 19 ⁇ 10 6 IU / ml of IL-2, and 190-210 mM L-glutamine (L -glutamine) was incorporated into a 25 cm 2 first culture vessel in which an anti-CD3 antibody containing 29 to 32 ml of a culture medium containing 350 to 430 ⁇ l and 2 to 5 ml of autologous plasma was added. Incubate for 30 minutes to 2 hours in 2 incubators.
- lymphocytes are first suspended in a small amount of the culture medium, and then mixed with the culture medium to which IL-2, L-glutamine and autologous plasma are added, thereby reducing the loss of lymphocyte cells and adding a small amount of IL-2, Loss of L-glutamine and autologous plasma can be prevented.
- lymphocytes are cultured in a state in which a monoclonal anti-CD3 antibody is solidified in a culture vessel, which induces the expression and secretion of factors that proliferate NK cells by inducing T cell activity at the beginning of culture by the anti-CD3 antibody.
- a monoclonal anti-CD3 antibody is solidified in a culture vessel, which induces the expression and secretion of factors that proliferate NK cells by inducing T cell activity at the beginning of culture by the anti-CD3 antibody.
- culturing for an appropriate time is very important for raising the proportion of NK cells.
- the culture mixture in the first culture vessel in which the anti-CD3 antibody was solidified was transferred to a second culture vessel in 25 cm 2 in which the anti-CD3 antibody was solidified, and 3 to 10 ⁇ l of 90-12 to 110 ⁇ g / ml IL-12 and 0.9 to 1.1.
- 2-30 ⁇ l of the anti-CD16 antibody of mg / ml was added and incubated for 1 hour to 3 hours in a 37 ° C. CO 2 incubator, followed by 10-30 ⁇ l of 90-18 to 110 ⁇ g / ml of IL-18. It is added to a second culture vessel of 25 cm 2 and incubated for 48 to 78 hours. In this case, 2 to 30 ⁇ l of 0.9 to 1.1 mg / ml of anti-CD3 antibody is solidified in the first culture vessel and the second culture vessel.
- IL-12 and anti-CD16 antibody are added to the second culture vessel at the same time, which increases the activity of transcription factor and increases the expression of INF- ⁇ than the IL-12 and anti-CD16 antibody. Induction can promote the proliferation and activity of NK cells.
- IL-18 is an essential factor for the production of INF- ⁇ , and since IL-12 receptor expression is induced by IL-12, it is preferably added to the second culture vessel after IL-12 addition.
- the culture mixture prepared in the first culture step is mixed with a culture medium to which IL-2, L-glutamine, and autologous plasma are added, and then cultured in the presence of IL-12 and anti-CD16 antibody, and then IL-18 is added thereto.
- the specific process is as follows.
- various culture mediums containing nutrients essential for cell growth and survival such as amino acids, vitamins, organic-inorganic compounds, and proteins, may be used as in the previous two steps. It is preferable to contain 200 IU / ml.
- the number of NK cells, T cells and NKT cells increases in a large amount and the size of each cell also increases. in that finally the total number of cells that was 2.0x10 6 ⁇ 4.0x10 7 it was found that it increased to 1.0x10 9 ⁇ 3.0x10 9.
- Lymphocytes 1 ⁇ 10 7 cells obtained from 60 cc of peripheral blood of the patient were suspended in 1 ml of culture medium, and then incorporated into 9 ml of culture medium containing IL-2, L-glutamine and autologous plasma.
- a first culture step of 4 days culture in the presence of IL-18, anti-CD3 and anti-CD16 antibodies was performed.
- the first culture step based on the culture medium of 39ml, 400 ⁇ l of 200mM L-glutamine and 4ml of autologous plasma, which acts as a nutrient for immune cell culture, and 18 ⁇ for activation of immune cells. 1 mg to control the relative composition of the final cultured immune cells with 4 ⁇ l of 10 6 IU / ml IL-2, 4 ⁇ l of 100 ⁇ g / ml IL-12 and 20 ⁇ l of 100 ⁇ g / ml IL-18 A culture medium in which 2.5 ⁇ l of anti-CD3 and anti-CD16 antibody was added was added.
- the culture mixture obtained through the first culture step was incorporated into 30 ml of the culture solution containing IL-2, L-glutamine and autologous plasma, and added for 2 days in the presence of IL-12, IL-18 and anti-CD16 antibodies.
- a second culture step of culturing was performed.
- the second culture step based on 67 ml of the culture medium, 670 ⁇ l and 5 ml of autologous plasma of 200 mM L-glutamine, which acts as a nutrient for immune cell culture, and 18 ⁇ for activation of immune cells. 1 mg to control the relative composition of the final cultured immune cells with 6.5 ⁇ l of 10 6 IU / ml IL-2, 8 ⁇ l of 100 ⁇ g / ml IL-12 and 40 ⁇ l of 100 ⁇ g / ml IL-18 A culture solution with 5 ⁇ l / mL of antiCD16 antibody was used.
- 3 and 4 are graphs showing phenotypic changes of lymphocytes before and after culture, where the H1 region shows NK cells, the H4 region shows T cells, the H2 region shows NKT cells, and the H3 region shows the distribution of other immune cells. It is a graph showing the change of NK cell number obtained through the self-activated lymphocyte culture method according to the present invention and the change of NK cell number obtained through the self-activated lymphocyte culture method according to the prior art.
- the activated lymphocytes cultured by the present invention are extracted from human peripheral blood by the ratio of NK cells due to the action of additives such as IL-12 and IL-18 added to promote the activation of NK cells.
- Ratio of NK cells in activated lymphocytes cultured by the applicant's conventional culture method (Korean Patent Laid-Open No. 2008-0053929), wherein the lymphocytes were cultured in the presence of IL-2 and anti-CD3, anti-CD16 and anti-CD56 antibodies.
- the percentage of NK cells in the activated lymphocytes was increased by about 20 to 30%, and the increase in the percentage of such NK cells was shown to express a more improved therapeutic effect through the titer analysis described below. It can be confirmed that the direct connection.
- FIG. 6 is a graph showing a result of comparing the results of titer analysis for activated lymphocytes cultured through the self-activated lymphocyte culture method according to the present invention and the results of titer analysis for activated lymphocytes cultured through the conventional method. .
- activated lymphocytes cultured by the method of Example 1 are used as effector cells, and blood cancer cell line K562 is used as target cells, and the ratio of activated lymphocytes to cancer cells is 10. Titer analysis was performed to determine the killing capacity of activated lymphocytes against hematologic cancer cell lines by setting to 1: 1.
- titer analysis was performed using activated lymphocytes cultured by the applicant's conventional culture method as effector cells under the same conditions as the above titer assay, and the results of each titer analysis are shown in FIG. 6.
- the average titer of activated lymphocytes cultured by the conventional culture method is 47%, whereas the average titer of activated lymphocytes cultured by the present invention is 93%, the activated lymphocytes cultured by the present invention It can be seen that the cancer cell killing ability showed about 2 times more than the activated lymphocytes cultured by the conventional culture method.
- the lymphocytes before the culture applied in this Example has a titer of 5% or less on average, it can be seen that the improvement in the titer of activated lymphocytes cultured by the present invention is at least 20 times higher than before the culture.
- the medium composition for self-activating lymphocyte culture and the method for culturing self-activated lymphocytes using the same according to the present invention efficiently amplify and activate NK cells, T cells, and NKT cells, and at the same time, the relative proportion of NK cells in the lymphocyte cells is better.
- the prognosis of cancer patients suffering from various types of malignant tumors by increasing the number of cancer cells that do not express MHC through mass activated NK cells can be applied to quantum immunotherapy with less side effects and less administration. Can be used to maximize improvement.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (14)
- 세포 배양용 배지와, 상기 세포 배양용 배지에 첨가되는 첨가제로 구성되어 자기 활성화 림프구를 대량 배양하기 위한 배지 조성물에 있어서,상기 첨가제는, 인터루킨-2(IL-2), 인터루킨12(IL-12), 인터루킨18(IL-18), 항CD3 및 항CD16 항체를 포함하여 구성되는 것을 특징으로 하는 자기활성화 림프구 배양용 배지 조성물.
- 제 1항에 있어서,상기 세포 배양용 배지에는,800 ~ 1200 IU(International Unit)/㎖의 IL-2가 함유된 것을 특징으로 하는 자기활성화 림프구 배양용 배지 조성물.
- 제 1항에 있어서,상기 세포 배양용 배지에 첨가되는 첨가제는,상기 세포 배양용 배지 39㎖를 기준으로 하였을 때,17×106 ~ 19×106 IU/㎖의 IL-2 3 ~ 10㎕와, 90 ~ 110㎍/㎖의 IL-12 3 ~ 10㎕와, 90 ~ 110㎍/㎖의 IL-18 10 ~ 30㎕와, 0.9 ~ 1.1㎎/㎖의 항CD3 항체 2 ~ 40㎕ 및 0.9 ~ 1.1㎎/㎖의 항CD16 항체 2 ~ 40㎕로 구성되는 것을 특징으로 하는 자기활성화 림프구 배양용 배지 조성물.
- 제 3항에 있어서,상기 첨가제에는,상기 세포 배양용 배지 39㎖를 기준으로 하였을 때,190 ~ 210mM의 L-글루타민(L-glutamine) 350 ~ 430㎕ 및 2 ~ 5㎖의 자가 유래 혈장(plasma)이 더 포함되는 것을 특징으로 하는 자기활성화 림프구 배양용 배지 조성물.
- 제 1항에 있어서,상기 세포 배양용 배지에 첨가되는 첨가제는,상기 세포 배양용 배지 67㎖를 기준으로 하였을 때,17×106 ~ 19×106 IU/㎖의 IL-2 3.5 ~ 7.8㎕와, 90 ~ 110㎍/㎖의 IL-12 2 ~ 10㎕와, 90 ~ 110㎍/㎖의 IL-18 20 ~ 50㎕ 및 0.9 ~ 1.1㎎/㎖의 항CD16 항체 4 ~ 80㎕로 구성되는 것을 특징으로 하는 자기활성화 림프구 배양용 배지 조성물.
- 제 5항에 있어서,상기 첨가제에는,상기 세포 배양용 배지 67 ㎖를 기준으로 하였을 때,190 ~ 210mM의 L-글루타민(L-glutamine) 650 ~ 740 ㎕ 및 2 ~ 5 ㎖의 자가 유래 혈장(plasma)이 더 포함되는 것을 특징으로 하는 자기활성화 림프구 배양용 배지 조성물.
- 인간의 말초혈액으로부터 림프구를 추출하는 단계와;상기 추출된 림프구를 인터루킨2(IL-2), L-글루타민(L-glutamine) 및 자가 유래 혈장(plasma)이 첨가된 배양액에서 인터루킨12(IL-12), 인터루킨18(IL-18), 항CD3 및 항CD16 항체의 존재하에 배양하는 제1배양단계; 및상기 제1배양단계에서 배양완료된 배양혼합액을 IL-2, L-글루타민 및 자가 유래 혈장이 첨가된 배양액에 혼입하여 IL-12/항CD16 항체와 IL-18의 존재하에 배양하는 제2배양단계;를 포함하여 구성되는 것을 특징으로 하는 자기활성화 림프구 배양방법.
- 제 7 항에 있어서,상기 제1배양단계는,상기 추출된 림프구를 IL-2, L-글루타민 및 자가 유래 혈장이 첨가된 배양액에서 항CD3 항체가 고형화된 제1배양용기 내에서 먼저 배양시키고, 상기 제1배양용기 내의 배양혼합액을 제2배양용기로 옮겨 IL-12와 항CD16 항체를 첨가하여 다시 배양시킨 다음, 상기 제2배양용기 내에 IL-18을 첨가하여 추가로 배양시키는 것을 특징으로 하는 자기활성화 림프구 배양방법.
- 제 7 항에 있어서,상기 제1배양단계는,상기 추출된 림프구를 IL-2, L-글루타민 및 자가 유래 혈장이 첨가된 배양액이 담겨있는 항CD3 항체가 고형화된 제1배양용기 내에서 30분 내지 2시간 배양하고, 상기 제1배양용기 내의 배양혼합액을 제2배양용기로 옮겨 IL-12와 항CD16 항체를 첨가하여 1시간 내지 3시간 배양한 다음, 상기 제2배양용기 내에 IL-18을 첨가하여 48시간 내지 72시간 배양하고, 이후, 상기 제2배양용기 내에 IL-2, L-글루타민 및 자가 유래 혈장이 첨가된 배양액을 추가하면서 12시간 내지 18시간 배양한 다음, 상기 제2배양용기 내의 배양혼합액을 제3배양용기로 옮겨 IL-2, L-글루타민 및 자가 유래 혈장을 추가하여 2일 내지 3일간 배양하는 것을 특징으로 하는 자기활성화 림프구 배양방법.
- 제 7 항에 있어서,상기 제2배양단계는,상기 제1배양단계를 거친 배양혼합액을 IL-2, L-글루타민 및 자가 유래 혈장이 첨가된 배양액에 IL-12 및 항CD16 항체를 첨가하여 먼저 배양시킨 다음, 상기 배양된 배양 혼합액에 IL-18을 첨가하여 추가로 배양시키는 것을 특징으로 하는 자기활성화 림프구 배양방법.
- 제 7 항에 있어서,상기 제2배양단계는,IL-2, L-글루타민 및 자가 유래 혈장이 첨가된 배양액이 담겨 있는 제4배양용기에 상기 제1배양단계를 거친 배양혼합액을 혼입하여 1시간 내지 3시간 배양하고, 이후 상기 제4배양용기에 IL-18을 첨가하여 12시간 내지 18시간 배양한 후, IL-2, L-글루타민 및 자가 유래 혈장이 첨가된 배양액을 추가하면서 항CD16 항체를 첨가하여 12시간 내지 18시간 배양하는 것을 특징으로 하는 자기활성화 림프구 배양방법.
- 제 7 항에 있어서,상기 제1 및 제2배양단계에서 사용되는 배양액은,IL-2를 800 ~ 1200 IU(International Uint)/㎖ 포함하고 있는 것을 특징으로 하는 자기활성화 림프구 배양방법.
- 제 7 항에 있어서,상기 자기활성화 림프구 배양방법은,상기 제2배양단계를 거친 배양혼합액에 자가 유래 혈장을 첨가하고, 상기 자가 유래 혈장이 첨가된 배양혼합액을 배양액이 들어 있는 가스투과성 배양백에 주입한 후 배양시키는 제3배양단계를 더 포함하는 것을 특징으로 하는 자기활성화 림프구 배양방법.
- 제 13 항에 있어서,상기 제3배양단계에서 사용되는 배양백은,IL-2를 100 ~ 200 IU/㎖ 포함하고 있는 것을 특징으로 하는 자기활성화 림프구 배양방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011800418765A CN103080302A (zh) | 2010-08-30 | 2011-06-01 | 自激淋巴球培养用培养基合成物及利用此的自激淋巴球培养方法 |
US13/819,426 US20130157364A1 (en) | 2010-08-30 | 2011-06-01 | Medium composition for culturing self-activated lymphocytes and method for culturing self-activated lymphocytes using same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100083836A KR101039843B1 (ko) | 2010-08-30 | 2010-08-30 | 자기활성화 림프구 배양용 배지 조성물 및 이를 이용한 자기활성화 림프구 배양방법 |
KR10-2010-0083836 | 2010-08-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012030057A2 true WO2012030057A2 (ko) | 2012-03-08 |
WO2012030057A3 WO2012030057A3 (ko) | 2012-04-26 |
Family
ID=44405225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/004013 WO2012030057A2 (ko) | 2010-08-30 | 2011-06-01 | 자기활성화 림프구 배양용 배지 조성물 및 이를 이용한 자기활성화 림프구 배양방법 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20130157364A1 (ko) |
KR (1) | KR101039843B1 (ko) |
CN (1) | CN103080302A (ko) |
WO (1) | WO2012030057A2 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2947144A4 (en) * | 2013-01-15 | 2016-06-08 | Hiroyuki Abe | METHOD FOR PRODUCING AN IMMUNOZYTIC COMPOSITION AND COMPOSITION FOR THE TREATMENT OF CANCER |
CN115044549A (zh) * | 2022-08-12 | 2022-09-13 | 北京科途医学科技有限公司 | 用于保持免疫细胞多样性的培养基和细胞组合物的培养方法 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5572863B2 (ja) * | 2011-06-24 | 2014-08-20 | 国立大学法人九州大学 | Nk細胞の増幅方法 |
KR101415039B1 (ko) | 2013-09-30 | 2014-08-13 | 지엔에스바이오(주) | 자기유래 활성화 림프구의 대량 증식을 위한 배지 조성물 및 배양방법 |
JP6405690B2 (ja) * | 2014-05-09 | 2018-10-17 | 東洋製罐グループホールディングス株式会社 | 複室培養容器、及び細胞培養方法 |
CN105462923B (zh) * | 2014-12-17 | 2018-11-02 | 山东大学第二医院 | 一种人自然杀伤细胞体外高效扩增方法 |
KR101909879B1 (ko) * | 2015-06-24 | 2018-10-19 | 주식회사 차바이오텍 | 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물 |
CN105462924B (zh) * | 2015-12-04 | 2019-01-18 | 广州赛莱拉干细胞科技股份有限公司 | Nk细胞的培养方法及无血清培养基组合 |
KR101683614B1 (ko) * | 2016-02-15 | 2016-12-07 | 신동혁 | Nk세포배양용 배지첨가키트 및 상기 키트를 이용한 nk세포배양방법 |
KR101969045B1 (ko) * | 2016-11-22 | 2019-04-19 | 신동혁 | 면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물 |
CN106434556B (zh) * | 2016-11-22 | 2019-10-11 | 上海新长安生物科技有限公司 | 一种体外诱导扩增i型nkt细胞的方法 |
WO2018110892A2 (ko) * | 2016-12-12 | 2018-06-21 | 주식회사 이뮤니스바이오 | 대식세포와 염증성물질을 이용한 자연살해세포의 대량증식방법 |
KR102419960B1 (ko) * | 2019-03-15 | 2022-07-13 | (주) 테라베스트 | 세포 조성물, 이의 제조 방법 및 이를 포함하는 아토피 예방 또는 치료용 약학 조성물 |
KR102216710B1 (ko) * | 2019-03-27 | 2021-02-17 | 신지섭 | Nk세포배양배지용 첨가조성물, 상기 첨가조성물을 이용한 nk세포배양방법 및 상기 배양방법으로 얻어진 피부트러블개선용 화장료조성물 |
KR20220036287A (ko) * | 2020-09-15 | 2022-03-22 | 주식회사 티에스바이오 | 고순도 및 고효율의 자연살해세포 제조방법 및 이의 용도 |
EP4230728A1 (en) * | 2020-09-15 | 2023-08-23 | Shin, Ji-Seop | Immune cell proliferation/activation kit and immune cell culture method using same proliferation/activation kit |
CN112746056A (zh) * | 2021-03-17 | 2021-05-04 | 辽宁盛京干细胞科技有限公司 | 一种增强nk细胞毒作用的培养液及其制备方法 |
KR102504039B1 (ko) * | 2022-10-25 | 2023-03-02 | 오정훈 | 자연살해세포 증식에 효과적인 배양 방법 및 이의 용도 |
CN115651903B (zh) * | 2022-11-14 | 2023-03-17 | 四川新生命干细胞科技股份有限公司 | 高杀伤力的免疫细胞群及其培养方法、试剂组合物和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090127974A (ko) * | 2008-06-10 | 2009-12-15 | 주식회사 엔케이바이오 | 자기활성화 림프구 배양용 배지 조성물 |
KR20090127973A (ko) * | 2008-06-10 | 2009-12-15 | 주식회사 엔케이바이오 | 자기활성화 림프구 배양 방법 |
KR101133185B1 (ko) * | 2008-07-29 | 2012-04-06 | 서울대학교병원 | 자연살해세포의 증식방법 |
-
2010
- 2010-08-30 KR KR1020100083836A patent/KR101039843B1/ko not_active IP Right Cessation
-
2011
- 2011-06-01 CN CN2011800418765A patent/CN103080302A/zh active Pending
- 2011-06-01 WO PCT/KR2011/004013 patent/WO2012030057A2/ko active Application Filing
- 2011-06-01 US US13/819,426 patent/US20130157364A1/en not_active Abandoned
Non-Patent Citations (5)
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2947144A4 (en) * | 2013-01-15 | 2016-06-08 | Hiroyuki Abe | METHOD FOR PRODUCING AN IMMUNOZYTIC COMPOSITION AND COMPOSITION FOR THE TREATMENT OF CANCER |
TWI612137B (zh) * | 2013-01-15 | 2018-01-21 | Hiroyuki Abe | 含免疫細胞之組成物的製造方法及癌症治療用組成物 |
KR101923848B1 (ko) | 2013-01-15 | 2018-11-29 | 히로유키 아베 | 면역세포 함유 조성물의 제조방법 및 암 치료용 조성물 |
US10160952B2 (en) | 2013-01-15 | 2018-12-25 | Hiroyuki Abe | Method for manufacturing an immune cell-containing composition, and a cancer-treating composition |
CN115044549A (zh) * | 2022-08-12 | 2022-09-13 | 北京科途医学科技有限公司 | 用于保持免疫细胞多样性的培养基和细胞组合物的培养方法 |
Also Published As
Publication number | Publication date |
---|---|
US20130157364A1 (en) | 2013-06-20 |
WO2012030057A3 (ko) | 2012-04-26 |
KR101039843B1 (ko) | 2011-06-09 |
CN103080302A (zh) | 2013-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012030057A2 (ko) | 자기활성화 림프구 배양용 배지 조성물 및 이를 이용한 자기활성화 림프구 배양방법 | |
JP6869994B2 (ja) | Nk細胞培養用培地添加キット、及びキットを用いるnk細胞培養方法 | |
KR101643165B1 (ko) | 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법 | |
KR20090127974A (ko) | 자기활성화 림프구 배양용 배지 조성물 | |
Rohrer et al. | CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. | |
Lundqvist et al. | Intraepithelial lymphocytes in human gut have lytic potential and a cytokine profile that suggest T helper 1 and cytotoxic functions. | |
KR20090127973A (ko) | 자기활성화 림프구 배양 방법 | |
WO2010047475A2 (ko) | 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법 | |
WO2015039100A1 (en) | Cd137 enrichment for efficient tumor infiltrating lymphocyte selection | |
EP1501918A1 (en) | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance | |
US20130323832A1 (en) | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance | |
WO2022102887A1 (ko) | Nk 세포의 대량증식 배양방법 | |
US11473059B2 (en) | Method for enrichment and expansion of virus antigen-specific T cells | |
JP2012532624A (ja) | 細胞、組成物および方法 | |
WO2021251707A1 (ko) | Nk 세포의 활성화 및 증폭을 위해 유전적으로 조작된 세포주, 및 그의 용도 | |
CN114686428B (zh) | 细胞-多肽偶联物及其制备方法和应用 | |
WO2024090703A1 (ko) | 자연살해세포 증식에 효과적인 배양 방법 및 이의 용도 | |
WO2019168222A1 (ko) | 말초혈액단핵구 유래 항암 활성화 림프구 배양용 배지 조성물 및 이를 이용한 항암 활성화 림프구 배양방법 | |
CN117018036A (zh) | 巨球形菌属细菌在制备治疗癌症的药物中的应用 | |
WO2020172638A1 (en) | Crispr/cas9 knock-out of cd33 in human hematopoietic stem/ progenitor cells for allogenic transplantation | |
WO2021251708A1 (ko) | Nk 세포의 활성화 및 증폭을 위해 유전적으로 조작된 세포주, 및 그의 용도 | |
WO2020180065A1 (ko) | 제대혈 단핵세포에서의 자연살해세포의 제조 방법 | |
Martın et al. | Characterization of a new subpopulation of mouse CD8α+ B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential | |
Gu et al. | Type 1 Regulatory T Cells and Their Application in Cell Therapy | |
WO2024071671A1 (ko) | 면역세포 및 자연살해세포 배양을 위한 신규한 이중배양 제조방법 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180041876.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11822032 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13819426 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11822032 Country of ref document: EP Kind code of ref document: A2 |